难治/复发性弥漫大B细胞型淋巴瘤的治疗现状及过继免疫治疗在其中的应用
摘要
弥漫大B细胞淋巴瘤是成人非霍奇金淋巴瘤中发病率最高的一种病理类型,其恶性程度较高,完全缓解率较低,耐药率较高。CIK及CAR-T细胞为代表的过继免疫治疗是近年来转化医学领域研究的重点及热点,CAR-T细胞以其靶向性、杀瘤活性、持久性等特点给难治/复发型弥漫大B细胞淋巴瘤的治疗带来新的希望。
出处
《中华保健医学杂志》
2016年第5期431-433,共3页
Chinese Journal of Health Care and Medicine
基金
军队保健专项科研课题(13BJZ47)
军队医药卫生科研基金课题(CWS12J025)
解放军总医院临床科研扶持基金(2013FC-TSYS-1020)
参考文献23
-
1Chenderfer JN,Dudley ME,Kassim SH,et al. Chemotherapy- refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD 19 chimeric antigen receptor[J]. J Clin Oncol, 2015,33 (6) :540-549.
-
2Ohmachi K,Niitsu N,Uchida T, et al. Muhicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma [J]. J Clin Oncol, 2013,31(17) :2103-2109.
-
3Perry AM,Crocket TD,Dave BJ,et al. B-cell lymphoma, unclassifiable,with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases [J]. Br J Haematol,2013,162(4) :40-49.
-
4Ott G,Rosenwald A,Camp OE. Understanding MYC- driven aggressive B-cell lymphomas: pathogenesis and classification ~J]. Blood,2013,122(24):3884-3891.
-
5Coiffier B,Radford J, Bosly A, et al. A multicentre,phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma [ J 1. Br J Haematol, 2013,163 (3) : 334 -342.
-
6den.Hollander J,Rimpi S,Doherty JR,et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state[J]. Blood,2010,116(9) : 1498- 1505.
-
7Zhou P, Liang P, Dong B,et al. Phasel clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma [J]. Cancer Biol Ther,2011,11 (5): 450-456.
-
8Beaty GL, Has AR, Maus MV, et al.Mesothelin- specific chimeric antigen receptor mRNA-enginered T cels induce anti-tumor activity in solid malignancies IJ].Cancer Immunol Res,2014,2 (2):112-120.
-
9Melenhorst J,Levine BL.Innovation and opportunity for chimeric antigen receptor targeted T cells [Jl. Cytotherapy,2013,15 (9) : 1046-1053.
-
10Scheuermann RH,Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy[J]. Leukemia Lymphoma,1995,18(5-6) :385-397.
-
1宋成村,薛宏伟,赵燕伟,王坤,王宣.生长抑素受体亚型SSTR2、SSTR3在淋巴瘤中的表达及临床意义(英文)[J].现代生物医学进展,2012,12(22):4351-4354. 被引量：1
-
2叶娴,李汉冲,张晓黎,茹脐华,谭洁,程骁赪,石晓菁.R-CHOP方案治疗17例弥漫大B细胞型淋巴瘤临床观察[J].中国血液流变学杂志,2007,17(3):386-388. 被引量：4
-
3陈英,吴晖,陈宁斌,黄雪珍,杨瑜,何鸿鸣,陈道光.R-CHOP方案治疗25例初治弥漫大B细胞型淋巴瘤的临床观察[J].肿瘤基础与临床,2009,22(5):398-399. 被引量：3
-
4杨绍灵,苏鹏,施玲玲.利妥昔单抗联合CHOP与单用CHOP方案治疗初治弥漫大B细胞型淋巴瘤的对比研究[J].现代肿瘤医学,2011,19(10):2069-2071. 被引量：13
-
5徐娟,宗宜干,唐晓文.FA方案治疗难治/复发性急性髓系白血病的临床观察[J].中国血液流变学杂志,2007,17(4):569-570. 被引量：3
-
6叶娴,李汉冲,张晓黎,茹脐华,谭洁,程骁赪,石晓菁.R-CHOP方案治疗17例弥漫大B细胞型淋巴瘤[J].肿瘤学杂志,2007,13(6):484-485.
-
7王中泰,周郅隆.顺铂腹腔注射联合化疗治疗晚期及复发型卵巢癌——4年回顾[J].上海医学,1990,13(8):453-456. 被引量：1
-
8陆德炎,吴芳颐.复发型急性白血病预后因素的研究[J].中华血液学杂志,1993,14(1):40-41. 被引量：2
-
9罗佳,黄跃.Survivin基因与胃癌关系的研究进展[J].南昌大学学报（医学版）,2014,54(9):96-98.
-
10段小琼,何文华,唐宁宁,王欣,唐雪梅.利妥昔单抗联合化疗初治CD20阳性弥漫大B细胞型淋巴瘤的疗效观察[J].中文科技期刊数据库（引文版）医药卫生,2015,1(6):13-13.
